| Revenue growth | 23% YoY in Q4 FY26; FY26 revenue ₹940.5 cr. |
|---|---|
| Margins | Q4 EBITDA margin expanded to 17.73% from 13.17% YoY. |
| Demand visibility | High; 203 State FDA approvals received for Indore facility. |
Growth
Q4 FY26 revenue grew 23% YoY to ₹252.1 cr; EBITDA increased 65.5% YoY to ₹44.7 cr.
Outlook
Targeting 5-10% market share in key geographies. Indore facility expected to reach EBITDA breakeven in FY26 and margin accretive state by FY27.
Risks
Structural operating model changes in the Sparsh division temporarily compressed Q3/Q4 revenue. High regulatory compliance risks for export markets.
Earnings Call filed with BSE, NSE: GUFICBIO. Summary written with AI assistance from the document.
Gufic BioSciences Ltd: key numbers
- Share price
- ₹423.75
- Market cap
- ₹4,249 Cr
- Revenue (annual)
- ₹944.0 Cr
- Net profit (annual)
- ₹64.21 Cr
- P/E (TTM)
- 57.9×Sector 50.4×
- Promoter holding
- 72.50%+0.00% QoQ
- FII holding
- 0.47%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Gufic BioSciences Ltd
All →Gufic BioSciences Legal & Regulatory
NSE rejected Gufic Biosciences' waiver application regarding a ₹1.72 lakh penalty for Regulation 17(1A) non-compliance. The company will pay the fine by October 03, 2026.
- Value
- ₹0.02 Cr
Gufic BioSciences Credit Rating
Gufic Biosciences announced that CRISIL Ratings has reaffirmed its credit ratings on the company's total bank loan facilities of ₹516 Crore.
- Value
- ₹516.0 Cr
Gufic BioSciences Annual General Meeting
Gufic Biosciences held its 42nd Annual General Meeting on September 4, 2026, where shareholders adopted financial statements and approved the final dividend declaration.
Gufic BioSciences Management Change
Gufic Biosciences Limited announced the promotions of Ms. Ami Shah to Head-Legal and Mr. Pinak Padhya to President of Sales & Marketing, effective September 2, 2026.
Gufic BioSciences Earnings Call Transcript: Key Takeaways
Gufic reports strong Q1 FY27 growth, driven by Indore plant ramp-up and expansion into high-margin complex injectables like GLP-1 (Semaglutide) and Botulinum Toxin.
- Call
- Guides 15% growth
Gufic BioSciences Investor Presentation: Key Takeaways
Gufic reported Q1 FY27 revenue of ₹260.8 Cr (+15% YoY) with EBITDA margins expanding to 18.09%. Strategy pivots toward IP-owned complex injectables and scaling the new Indore facility.